Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Biochemical recurrence

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    105 result(s) found for: Biochemical recurrence. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2018-001267-22 Sponsor Protocol Number: 65593 Start Date*: 2019-10-10
    Sponsor Name:Radboud University Medical Center
    Full Title: F18-PSMA-1007 PET for early biochemical recurrence of prostate cancer, comparison with 18F-Fluciclovine.
    Medical condition: Patients treated for non-metastasized prostate cancer with a biochemical recurrence of prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001036-21 Sponsor Protocol Number: PCaRestaging-PET/MR Start Date*: 2020-03-04
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Phase II monocentric study on prostate cancer restaging using PET/MR with innovative radiotracers
    Medical condition: Radically treated patient for prostate cancer presenting a biochemical recurrence of disease (PSA: > o = 0.2 ng/mL)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10026389 Malignant neoplasm of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004236-20 Sponsor Protocol Number: MN4 Start Date*: 2008-06-24
    Sponsor Name:AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA
    Full Title: PET-CT DIAGNOSIS OF CARCINOMA PROSTATICO WITH ALTERNATIVE TO FLUORODESOSSIGLUCOSIO Radio: 18F-COLINA
    Medical condition: Prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004952-13 Sponsor Protocol Number: DART Start Date*: 2020-12-14
    Sponsor Name:University Hospital Ghent
    Full Title: Stereotactic body radiotherapy with or without Darolutamide for OligoRecurrent prostate cancer: a randomized phase II trial (DART)
    Medical condition: - Prostate cancer patients with a biochemical recurrence following primary therapy - Hormone-sensitive - Up to 5 metastases on PSMA PET-CT
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071119 Hormone-dependent prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2021-003779-32 Sponsor Protocol Number: NL77171.091.21 Start Date*: 2021-09-27
    Sponsor Name:Radboud University Medical Center
    Full Title: HYPo-fractionated Radiotherapy of Lymph Node Metastases guided by NanO-MRI in Prostate Cancer Patients: A Pilot Study (HYPNO-study).
    Medical condition: men with biochemical recurrent prostate cancer after radical prostatectomy with ≤ 4 foci harbouring regional lymph node metastases (up to 6 lymph nodes in total) on nano-MRI.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-000680-22 Sponsor Protocol Number: SAG-37/DIV Start Date*: 2007-10-29
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomized, placebo-controlled, parallel group, multi-centre phase III clinical study on the efficacy and tolerability of mesalazine granules vs. placebo for the prevention of recurre...
    Medical condition: Diverticultits
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013538 Diverticulitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) NL (Completed) LV (Completed) LT (Completed) SK (Completed) EE (Completed) GB (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-003177-26 Sponsor Protocol Number: RT2019-13 Start Date*: 2020-02-05
    Sponsor Name:UMCG
    Full Title: Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy
    Medical condition: Patients with biochemical recurrence after primary treatment of prostate cancer presenting with ≤4 metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000328-85 Sponsor Protocol Number: FINNHT1 Start Date*: 2017-05-18
    Sponsor Name:Helsinki University Hospital, Obstetrics and Gynecology
    Full Title: Randomized comparative trial between abrupt and tapered mode of discontinuation of longterm hormone therapy: Impact on endothelial function, recurrence of vasomotor symptoms and quality of life
    Medical condition: We will assess the effects of hormone therapy termination on endothelial function using biophysical (flow-mediated dilation, peripheral artery tonometry) and biochemical markers. We will compare th...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10027311 Menopause flushing LLT
    20.0 10041244 - Social circumstances 10076936 Impaired quality of life PT
    20.1 10038604 - Reproductive system and breast disorders 10027301 Menopausal hot flushes LLT
    20.1 10022891 - Investigations 10060858 Cardiovascular function test PT
    20.0 10041244 - Social circumstances 10027308 Menopause PT
    16.1 10038604 - Reproductive system and breast disorders 10027309 Menopause and related conditions HLGT
    20.0 10007541 - Cardiac disorders 10007649 Cardiovascular disorder PT
    20.0 10041244 - Social circumstances 10051775 Postmenopause PT
    20.0 10047065 - Vascular disorders 10048554 Endothelial dysfunction PT
    Population Age: Adults Gender: Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-001679-36 Sponsor Protocol Number: ML41007 Start Date*: 2019-09-26
    Sponsor Name:Aarhus University
    Full Title: Treatment Of Metastic Bladder cancer at the time Of biochemical reLApse following radical cystectomy
    Medical condition: Biochemical relapse in patients who have undergone radical cystectomy because of muscle-invasive transitional cell carcinoma of the urinary bladder
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066754 Bladder transitional cell carcinoma stage III PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004397-99 Sponsor Protocol Number: MBCC28040 Start Date*: 2014-06-17
    Sponsor Name:Instituto Tecnológico PET, S.A.U. (ITP)
    Full Title: A Phase III Clinical Trial to evidence the safety and efficacy of the radio-drug 18f-Fluorocholine (18F-FCH), using Positron Emission Tomography (PET) for the diagnosis of the prostate carcinoma in...
    Medical condition: Prostate Carcinoma in patients with biochemical relapse.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-001291-42 Sponsor Protocol Number: MK-3475-C51 Start Date*: 2022-06-30
    Sponsor Name:Universitätsklinikum Freiburg
    Full Title: Radiotherapy in combination with pembrolizumab in patients with PSA persistence or biochemical recurrence after radical prostatectomy due to prostate cancer
    Medical condition: Recurrent prostate cancer - Patients with biochemical recurrence (BCR) or persisting prostate-specifiv antigen (PSA) after radical prostatectomy (RP)
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-015158-39 Sponsor Protocol Number: SAG-51/DIV Start Date*: 2010-05-06
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, dose-response, randomised, placebo-controlled, parallel group, multicentre phase III clinical study on the efficacy and tolerability of mesalazine granules vs. placebo for the prevent...
    Medical condition: Diverticulitis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10013538 Diverticulitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FI (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000625-37 Sponsor Protocol Number: BED-004 Start Date*: 2015-08-28
    Sponsor Name:Blue Earth Diagnostics Limited
    Full Title: A phase 3, open-label study to assess the clinical utility of fluciclovine (18F) PET/CT in patients with prostate cancer with biochemical recurrence after radical treatment
    Medical condition: Prostate cancer with biochemical recurrence after radical treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-005010-59 Sponsor Protocol Number: THERAG0001 Start Date*: 2018-05-17
    Sponsor Name:Theragnostics Ltd
    Full Title: A Phase II, Open-label Study to Assess Safety and Clinical Utility of 68Ga-THP-PSMA PET/CT in Patients with High Risk Primary Prostate Cancer or Biochemical Recurrence after Radical treatment
    Medical condition: High Risk Primary Prostate Cancer or Biochemical Recurrence after Radical treatment
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005993-24 Sponsor Protocol Number: MIP7 Start Date*: 2022-09-14
    Sponsor Name:ITEL TELECOMUNICAZIONI S.R.L.
    Full Title: Phase III Multicentre Prospective Comparative Study of Detection Rate of 18F-JK-PSMA-7 and of 18F-fluorocholine in Patients with Biochemical Recurrence of Prostate Cancer after Previous Treatment w...
    Medical condition: Patients with confirmed biochemical recurrence of Prostatic Cancer (PCa) after treatment with curative intention.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10036921 Prostate carcinoma LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017798-39 Sponsor Protocol Number: PROVAX study Start Date*: 2010-07-08
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: An open label, Phase II study of vaccination with Survivin peptides emulsified in Montanide ISA 51VG after IMP 321 injection in prostate carcinoma patients with biochemical failure (PROVAX study)
    Medical condition: Prostate cancer, biochemical failure after all potentially curative standard local therapies (radiotherapy, brachytherapy and surgery) or biochemical progression while patients have castrated level...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10001200 Adenocarcinoma of the prostate stage I LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011189-27 Sponsor Protocol Number: FCH_PET Start Date*: 2009-05-01
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: Phase III prospective clinical trial: 18F-FCH/PET evaluation in early diagnosis of disease recurrence in prostate cancer
    Medical condition: Clinical suspicion of disease relapse in prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036966 Prostatic neoplasms and hypertrophy HLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003523-16 Sponsor Protocol Number: ARN-I-20-DEU-003-V01 Start Date*: 2021-12-29
    Sponsor Name:Universität des Saarlandes
    Full Title: A feasibility trial investigating inductive Apalutamide therapy combined with radical prostatectomy in patients with locally advanced T4 high risk prostate cancer
    Medical condition: patients with locally advanced T4 high risk prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001123-40 Sponsor Protocol Number: RENARD Start Date*: 2021-09-08
    Sponsor Name:Amsterdam UMC, VU University Medical Center
    Full Title: 18F-fluciclovine PET/CT and 18F-DCFPyL PET/CT in patients with biochemical recurrence of disease after radical prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001059-15 Sponsor Protocol Number: 2021-PSMA-CZT Start Date*: 2022-04-05
    Sponsor Name:Fysiologiska Kliniken, Linköping US
    Full Title: The value of 99mTc-MIP-1404 SPECT/CT Veriton CZT for staging of prostate cancer and before primary therapy and in biochemical recurrence after radical prostatectomy. Fase II study.
    Medical condition: Prostate cancer. Please see the study protocol.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 09:42:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA